Institut de cancerologie de l'ouest (ICO)

Saint-Herblain 44805

1 studies enrolling now · 4 studies all time

What they study most

Advanced Breast Cancer, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Bladder Cancer, Breast Cancer, Castration-Resistant Prostatic Cancer, FGFR3 Gene Alteration, FGFR3 Gene Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Locally Advanced Urothelial Carcinoma, Metastatic Breast Cancer

Studies at this site

• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer — Running, not enrolling
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations — Running, not enrolling